2019
Pembrolizumab (pembro) for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of phase 3 KEYNOTE-040 prior radiation treatment (RT) and disease state.
Harrington K, Cohen E, Soulieres D, Dinis J, Licitra L, Ahn M, Soria A, Machiels J, Mach N, Mehra R, Burtness B, Lin J, Cheng J, Swaby R, Le Tourneau C. Pembrolizumab (pembro) for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of phase 3 KEYNOTE-040 prior radiation treatment (RT) and disease state. Journal Of Clinical Oncology 2019, 37: 6026-6026. DOI: 10.1200/jco.2019.37.15_suppl.6026.Peer-Reviewed Original ResearchPrior radiation treatmentSurvival benefitRadiation treatmentM diseaseEnd pointNeck squamous cell carcinomaDisease statesPrimary end pointSecondary end pointsPlatinum-based therapySquamous cell carcinomaITT populationCare chemotherapyMetastatic HNSCCRecurrent headCell carcinomaPembroInvestigator's choicePatientsDiseaseDefinitive conclusionsMetastaticPFSRecurrentTreatment
2018
1047PD Pembrolizumab for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of treatment options from the phase III KEYNOTE-040 trial
Le Tourneau C, Cohen E, Harrington K, Dinis J, Licitra L, Ahn M, Soria A, Machiels J, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby R, Soulières D. 1047PD Pembrolizumab for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of treatment options from the phase III KEYNOTE-040 trial. Annals Of Oncology 2018, 29: viii373-viii374. DOI: 10.1093/annonc/mdy287.003.Peer-Reviewed Original Research